DGAP-News

STRATEC reports on first half of 2015

DGAP-News: STRATEC Biomedical AG / Key word(s): Quarter
Results/Interim Report
STRATEC reports on first half of 2015

23.07.2015 / 07:33

---------------------------------------------------------------------

STRATEC reports on first half of 2015

- Sales of EUR 70.0 million in 6M/2015 (+1.4%; 6M/2014: EUR 69.1 million)
- EBIT of EUR 12.0 million in 6M/2015 (+6.7%; 6M/2014: EUR 11.2 million*)
- EBIT margin of 17.1% in 6M/2015 (+80 basis points; 6M/2014: 16.3%*)
- Earnings per share of EUR 0.83 in 6M/2015 (+1.2%; 6M/2014: EUR 0.82*)
- Ongoing positive development expected for financial year as a whole

Birkenfeld, July 23, 2015

STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard,
TecDAX) today announced its results for the period from January 1, 2015 to
June 30, 2015 upon the publication of its Interim Report as of June 30,
2015.

Key figures (EUR 000s)     01.01.- 06.30.2015  01.01.- 06.30.2014   Change
Sales                                  70,012              69,050    +1.4%
EBIT                                   11,986             11,232*    +6.7%
EBIT margin (%)                          17.1               16.3*  +80 bps
Consolidated net income                 9,807              9,635*    +1.8%
Earnings per share (EUR)                 0.83               0.82*    +1.2%

bps = basis points

* 2014 figure adjusted to exclude a one-off negative item resulting from
the recognition in the first quarter of expenses for the remaining years of
the term of a management board contract for a retired member of the Board
of Management. Unadjusted EBIT for the first half of 2014 amounted to EUR
10.3 million; the corresponding EBIT margin amounted to 14.9%, consolidated
net income to EUR 8.9 million and earnings per share to EUR 0.76. The
actual amount of the aforementioned expense item may differ at the time of
payment from the amounts presented here.


Financial performance
The slight increase in sales, with growth of 1.4% from EUR 69.1 million to
EUR 70.0 million, was primarily attributable to the stable performance of
the analyzer system supply business and the positive developments in the
business with service parts. This product mix helped drive an improvement
in profitability, with the EBIT margin at 17.1%, up from 16.3% in the
previous year (unadjusted 2014 figure: 14.9%). Year-on-year, EBIT grew by
6.7% to EUR 12.0 million, consolidated net income increased by 1.8% to EUR